Bree Clare

Johnson & Johnson announced FDA approval of a supplemental new drug application for Caplyta (lumateperone) for the prevention of relapse in schizophrenia, based on compelling long-term clinical data and reported by Drugs.com. This label expansion reinforces Caplyta’s role within Johnson & Johnson’s comprehensive neuropsychiatric therapy portfolio and addresses a critical unmet need in schizophrenia management.

Novartis and PTC Therapeutics have advanced their Huntington’s disease candidate, votoplam, into Phase 3 development following promising mid-stage results. The decision reflects confidence in the program’s potential while signaling caution regarding the FDA approval pathway, according to market analysts and reported by BioSpace.com. The move comes as the partners prepare for a pivotal late-stage trial expected to deliver results in 2030.

BridgeBio’s Attruby (acoramidis) is positioning itself as a formidable competitor in the transthyretin amyloid cardiomyopathy (ATTR-CM) market, with new pivotal trial data and indirect comparisons suggesting potential advantages over Pfizer’s long-standing standard-of-care therapy, Vyndamax (tafamidis).